GeneDx Holdings Corp.

GeneDx Holdings Corp. operates as a genomics diagnostics company providing genetic testing services with primary focus on pediatric and rare disease identification. The company utilizes whole exome sequencing (WES) and whole genome sequencing (WGS) technologies to analyze patient genetic material and deliver diagnostic results. Beyond sequencing services, GeneDx develops and operates an artificial intelligence-based platform designed to process, analyze, and interpret next-generation sequencing data for clinical applications spanning rare disease, hereditary cancer risk, and cancer genomics.

The company maintains two primary business operations: its diagnostic testing services and its data analysis and interpretation platform. Revenue is generated through clinical laboratory testing services provided to healthcare systems, physicians, and patients seeking genetic diagnoses. The AI platform supports internal operations and can serve as a foundation for additional data services and information products.

GeneDx operates from its headquarters in Stamford, Connecticut with approximately 1,300 full-time employees. The company was founded in 2000 and incorporated in Delaware. As a Nasdaq-listed public company, GeneDx serves a geographically distributed patient population across the United States through its laboratory operations and clinical network partnerships.